FOXP3 and lung cancer: The MFI of GARP in Foxp3+ Tregs from lung cancer patients was also similar with that from the healthy controls [420.0 (153.0, 562.3) vs. 384.0 (332.8, 461.8), P = 0.6985], but compared with the proportion of GARP+ cell, the MFI of GARP in Foxp3+ Tregs was similar with that in Foxp3− Tconvs [420.0 (153.0, 562.3) vs. 463.0 (307.5, 494.5), P = 0.3338; 384.0 (332.8, 461.8) vs. 404.0 (354.8, 429.8), P = 0.9219] (Figure 1D).